A recent clinical study reported that serum adiponectin was higher in AD patients than in MCI patients, and adiponectin CSF levels were positively correlated with Aβ1-42 and cognitive function, suggesting that higher serum adiponectin in AD patients constitutes a strategy to compensate for possible central signaling defects [20]. Here, ADIPOQ is linked to Alzheimer disease.